Using the ALSFRS-R in multicentre clinical trials for amyotrophic lateral sclerosis: potential limitations in current standard operating procedures

Plateaus in amyotrophic lateral sclerosis progression: results from a population‐based cohort

(2020) R. Vasta et al.   EUROPEAN JOURNAL OF NEUROLOGY

Can video consultations replace face-to-face interviews? Palliative medicine and the Covid-19 pandemic: rapid review

(2020) Anna Elizabeth Sutherland et al.   BMJ Supportive & Palliative Care

Current trends in the clinical trial landscape for amyotrophic lateral sclerosis

(2020) Ruben P.A. van Eijk et al.   CURRENT OPINION IN NEUROLOGY

TRICALS: creating a highway toward a cure

(2020) Ruben P.A. van Eijk et al.   Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Development and assessment of the inter-rater and intra-rater reproducibility of a self-administration version of the ALSFRS-R

(2019) Leonhard A Bakker et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Criteria for site selection in industry-sponsored clinical trials: a survey among decision-makers in biopharmaceutical companies and clinical research organizations

(2019) Tilde Dombernowsky et al.   Trials

“ALS reversals”: demographics, disease characteristics, treatments, and co-morbidities

(2018) Daniel Harrison et al.   Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Amyotrophic lateral sclerosis

(2017) Michael A van Es et al.   LANCET

Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial

(2017) Vincent Meininger et al.   LANCET NEUROLOGY

How common are ALS plateaus and reversals?

(2015) Richard S. Bedlack et al.   NEUROLOGY

A further Rasch study confirms that ALSFRS-R does not conform to fundamental measurement requirements

(2015) Franco Franchignoni et al.   Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial

(2013) Merit E Cudkowicz et al.   LANCET NEUROLOGY

Factors influencing clinical trial site selection in Europe: the Survey of Attitudes towards Trial sites in Europe (the SAT-EU Study)

(2013) Marta Gehring et al.   BMJ Open

The Combined Assessment of Function and Survival (CAFS): A new endpoint for ALS clinical trials

(2013) James D. Berry et al.   Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration